JP2020511136A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511136A5 JP2020511136A5 JP2019550246A JP2019550246A JP2020511136A5 JP 2020511136 A5 JP2020511136 A5 JP 2020511136A5 JP 2019550246 A JP2019550246 A JP 2019550246A JP 2019550246 A JP2019550246 A JP 2019550246A JP 2020511136 A5 JP2020511136 A5 JP 2020511136A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- item
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 137
- 102000037865 fusion proteins Human genes 0.000 claims description 137
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 132
- 108020004707 nucleic acids Proteins 0.000 claims description 76
- 102000039446 nucleic acids Human genes 0.000 claims description 76
- 150000007523 nucleic acids Chemical class 0.000 claims description 76
- 230000002209 hydrophobic effect Effects 0.000 claims description 64
- 230000003834 intracellular effect Effects 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 56
- 239000013598 vector Substances 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 25
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 22
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 20
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 230000031146 intracellular signal transduction Effects 0.000 claims description 13
- 230000004068 intracellular signaling Effects 0.000 claims description 12
- 230000009149 molecular binding Effects 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 230000004083 survival effect Effects 0.000 claims description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 6
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 6
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 102000017578 LAG3 Human genes 0.000 claims description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 6
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 230000000139 costimulatory effect Effects 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 5
- 206010066476 Haematological malignancy Diseases 0.000 claims description 5
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 5
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 3
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- -1 CD86 Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102100031351 Galectin-9 Human genes 0.000 claims description 3
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 3
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 3
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 3
- 101001038037 Homo sapiens Lysophosphatidic acid receptor 5 Proteins 0.000 claims description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 3
- 102100040404 Lysophosphatidic acid receptor 5 Human genes 0.000 claims description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 3
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 102000007497 Patched-2 Receptor Human genes 0.000 claims description 3
- 108010071083 Patched-2 Receptor Proteins 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 102000011408 Tripartite Motif Proteins Human genes 0.000 claims description 3
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 description 28
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 28
- 238000000034 method Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 102000006306 Antigen Receptors Human genes 0.000 description 4
- 108010083359 Antigen Receptors Proteins 0.000 description 4
- 102000008160 Cyclin A1 Human genes 0.000 description 4
- 108010060267 Cyclin A1 Proteins 0.000 description 4
- 102000015212 Fas Ligand Protein Human genes 0.000 description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 description 4
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 4
- 102000003735 Mesothelin Human genes 0.000 description 4
- 108090000015 Mesothelin Proteins 0.000 description 4
- 102100022748 Wilms tumor protein Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 3
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 2
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000000428 immunological synapse Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000057542 human CD200R1 Human genes 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022097950A JP7465306B2 (ja) | 2017-03-17 | 2022-06-17 | 免疫調節性融合タンパク質およびその使用 |
| JP2024000159A JP2024019732A (ja) | 2017-03-17 | 2024-01-04 | 免疫調節性融合タンパク質およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473282P | 2017-03-17 | 2017-03-17 | |
| US62/473,282 | 2017-03-17 | ||
| US201862629663P | 2018-02-12 | 2018-02-12 | |
| US62/629,663 | 2018-02-12 | ||
| PCT/US2018/022998 WO2018170475A1 (en) | 2017-03-17 | 2018-03-16 | Immunomodulatory fusion proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022097950A Division JP7465306B2 (ja) | 2017-03-17 | 2022-06-17 | 免疫調節性融合タンパク質およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020511136A JP2020511136A (ja) | 2020-04-16 |
| JP2020511136A5 true JP2020511136A5 (enExample) | 2021-04-15 |
Family
ID=61911694
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550246A Pending JP2020511136A (ja) | 2017-03-17 | 2018-03-16 | 免疫調節性融合タンパク質およびその使用 |
| JP2022097950A Active JP7465306B2 (ja) | 2017-03-17 | 2022-06-17 | 免疫調節性融合タンパク質およびその使用 |
| JP2024000159A Withdrawn JP2024019732A (ja) | 2017-03-17 | 2024-01-04 | 免疫調節性融合タンパク質およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022097950A Active JP7465306B2 (ja) | 2017-03-17 | 2022-06-17 | 免疫調節性融合タンパク質およびその使用 |
| JP2024000159A Withdrawn JP2024019732A (ja) | 2017-03-17 | 2024-01-04 | 免疫調節性融合タンパク質およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11725210B2 (enExample) |
| EP (1) | EP3595706A1 (enExample) |
| JP (3) | JP2020511136A (enExample) |
| CN (2) | CN119409836A (enExample) |
| AU (1) | AU2018236461B2 (enExample) |
| CA (1) | CA3055784A1 (enExample) |
| MX (2) | MX2019010812A (enExample) |
| WO (1) | WO2018170475A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| US11725210B2 (en) | 2017-03-17 | 2023-08-15 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| CA3111384A1 (en) * | 2018-09-05 | 2020-03-12 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| EP3856769A4 (en) * | 2018-09-28 | 2022-08-17 | Memorial Sloan Kettering Cancer Center | IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF |
| GB2569692A (en) * | 2018-10-30 | 2019-06-26 | Tc Biopharm Ltd | T cell antigen receptor chimera |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| EP3897690A4 (en) * | 2018-12-19 | 2022-09-28 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| CA3129263A1 (en) * | 2019-02-08 | 2020-08-13 | Dna Twopointo Inc. | Transposon-based modifications of immune cells |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| WO2021046261A1 (en) * | 2019-09-05 | 2021-03-11 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CN114651068B (zh) * | 2019-09-16 | 2024-09-13 | 麦克马斯特大学 | 嵌合共刺激受体及其方法和用途 |
| CN110790842B (zh) * | 2019-11-25 | 2021-03-30 | 贵州康钦承平生物科技有限公司 | 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用 |
| AU2021206644A1 (en) * | 2020-01-06 | 2022-07-28 | Memorial Hospital For Cancer And Allied Diseases | Novel dominant negative Fas polypeptides, cells comprising thereof and uses thereof |
| US20230121433A1 (en) * | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| EP4132962A1 (en) | 2020-04-09 | 2023-02-15 | Autolus Limited | Molecule |
| CN115315439A (zh) * | 2020-04-09 | 2022-11-08 | 奥托路斯有限公司 | 细胞 |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| CN117843812A (zh) * | 2020-05-22 | 2024-04-09 | 重庆精准生物技术有限公司 | 逆转肿瘤微环境的融合蛋白及其应用 |
| CN116348485A (zh) | 2020-07-17 | 2023-06-27 | 英研生物(英国)有限公司 | 提供用于过继性细胞疗法的靶向共刺激的受体 |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| TW202306997A (zh) | 2021-06-16 | 2023-02-16 | 英商英斯特生物科技有限公司 | 用於在過繼細胞療法中提供標靶共刺激之受體 |
| EP4370213A4 (en) | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
| CN113621077B (zh) * | 2021-09-02 | 2023-01-31 | 山东大学 | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 |
| JP2024541501A (ja) * | 2021-11-25 | 2024-11-08 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | Ｃｄ９５ポリペプチド |
| EP4476246A4 (en) * | 2022-02-07 | 2026-05-13 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Recombinant proteins that stimulate an immune response in the presence of a naturally inhibitory ligand bond |
| EP4499680A1 (en) * | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| TW202402798A (zh) * | 2022-05-23 | 2024-01-16 | 美商艾費尼Ｔ醫療公司 | 對新抗原具特異性之結合蛋白與工程化細胞及其用途 |
| EP4293040A1 (en) | 2022-06-19 | 2023-12-20 | ETH Zurich | Cell line for engineering cytokine receptors |
| WO2024046468A1 (en) * | 2022-09-02 | 2024-03-07 | Nanjing Legend Biotech Co., Ltd. | Fusion proteins targeting lysosomal degradation pathway |
| KR20240095012A (ko) * | 2022-11-29 | 2024-06-25 | (주) 테라베스트 | Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도 |
| WO2024193714A1 (zh) * | 2023-03-23 | 2024-09-26 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
| WO2025006795A1 (en) * | 2023-06-30 | 2025-01-02 | Board Of Regents, The University Of Texas System | Tsyn-seq: a t cell synapse-based tumor antigen identification platform |
| WO2025081123A1 (en) | 2023-10-12 | 2025-04-17 | Fred Hutchinson Cancer Center | Methods and compositions for improving t cell immunotherapy |
| WO2025117773A2 (en) * | 2023-11-30 | 2025-06-05 | Affini-T Therapeutics, Inc. | Compositions and methods for treating neoplasia |
| EP4599843A1 (en) | 2024-02-09 | 2025-08-13 | Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau | Car and modified cd200r combination |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1999A (en) | 1841-03-12 | Improvement in seed-planters | ||
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| EP0737207B1 (en) | 1994-01-11 | 2004-09-22 | Dyax Corporation | Inhibitors of human plasmin derived from the kunitz domains |
| AU685693B2 (en) | 1994-11-01 | 1998-01-22 | Targeted Genetics Corporation | Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| EP1791865B1 (en) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cells expressing a modified t cell receptor |
| ATE423140T1 (de) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| WO2012012695A2 (en) | 2010-07-23 | 2012-01-26 | Fred Hutchinson Cancer Research Center | A method for the treatment of obesity |
| EP2621514B1 (en) | 2010-09-28 | 2016-09-21 | KAHR Medical (2005) Ltd | Compositions and methods for treatment of hematological malignancies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2694640B1 (en) | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| JP6074435B2 (ja) | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013192294A1 (en) * | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
| EP2941438A1 (en) | 2013-01-01 | 2015-11-11 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| WO2014110591A1 (en) | 2013-01-14 | 2014-07-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| CN103965361B (zh) | 2013-02-06 | 2018-10-30 | 上海细胞治疗工程技术研究中心集团有限公司 | 一种t细胞信号的嵌合分子转换器及其用途 |
| WO2014172584A1 (en) | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| EP3177314B1 (en) | 2014-08-04 | 2020-10-07 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| ES2751915T5 (es) | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| US10350245B2 (en) | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| PT3310805T (pt) | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| JP6976960B2 (ja) | 2015-11-27 | 2021-12-08 | カーサリクス プロプライエタリー リミテッド | 遺伝子改変された細胞およびその使用 |
| WO2017112944A1 (en) | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| EP4166161B1 (en) | 2016-04-14 | 2026-03-04 | Fred Hutchinson Cancer Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| JP7198670B2 (ja) * | 2016-04-20 | 2023-01-04 | フレッド ハッチンソン キャンサー センター | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 |
| US11725210B2 (en) | 2017-03-17 | 2023-08-15 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| WO2019061012A1 (zh) | 2017-09-26 | 2019-04-04 | 南京凯地生物科技有限公司 | 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用 |
| CN110330567B (zh) | 2019-07-02 | 2020-11-06 | 南京凯地生物科技有限公司 | 双特异性嵌合抗原受体t细胞，其制备方法和应用 |
-
2018
- 2018-03-16 US US16/494,729 patent/US11725210B2/en active Active
- 2018-03-16 EP EP18716423.1A patent/EP3595706A1/en active Pending
- 2018-03-16 CN CN202411496477.3A patent/CN119409836A/zh active Pending
- 2018-03-16 CA CA3055784A patent/CA3055784A1/en active Pending
- 2018-03-16 MX MX2019010812A patent/MX2019010812A/es unknown
- 2018-03-16 CN CN201880030106.2A patent/CN110621335B/zh active Active
- 2018-03-16 AU AU2018236461A patent/AU2018236461B2/en active Active
- 2018-03-16 WO PCT/US2018/022998 patent/WO2018170475A1/en not_active Ceased
- 2018-03-16 JP JP2019550246A patent/JP2020511136A/ja active Pending
-
2019
- 2019-09-11 MX MX2024000006A patent/MX2024000006A/es unknown
-
2022
- 2022-06-17 JP JP2022097950A patent/JP7465306B2/ja active Active
-
2023
- 2023-06-21 US US18/339,197 patent/US12365906B2/en active Active
-
2024
- 2024-01-04 JP JP2024000159A patent/JP2024019732A/ja not_active Withdrawn